In Brief: Matritech
This article was originally published in The Gray Sheet
Executive Summary
Matritech: Premarket approval application for the firm's NMP22 bladder cancer test will be reviewed by FDA's Immunology Devices Advisory Panel at its Nov. 30 meeting, Matritech announces Oct. 31. The test is designed to detect cancer cells' nuclear matrix proteins. Matritech submitted the PMA in November 1994 ("The Gray Sheet" June 19, p. 32). The firm also says it has terminated its co-marketing agreement with Hybritech for the NMP22 in the wake of Hybritech's acquisition by Beckman Instruments ("The Gray Sheet" Oct. 2, p. 3). Matritech plans to develop its own direct sales force for the microtiter plate kits and is in discussion with potential partners for marketing an automated version of the test...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.